×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Chinese Fibromyalgia Market Share

ID: MRFR/Pharma/4175-CR
85 Pages
Rahul Gotadki
March 2018

Chinese Fibromyalgia Market Research Report By Diagnosis (Laboratory Evaluation, Presence Of Central Sensitization), Treatment (Targeted (Antidepressants, Anti-Seizure Drugs), Symptomatic Treatment, End Users (Hospitals &Clinics) - Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Chinese Fibromyalgia Market Infographic
Purchase Options

Market Share

Chinese Fibromyalgia Market Share Analysis

Before implementing any strategy, it's crucial to comprehend the dynamics of the Chinese fibromyalgia market, including the prevalence of the condition, existing treatments, patient demographics, and competitor landscape. Differentiating the product or service offering is key to standing out in a crowded market. This could involve unique formulations, delivery methods, or ancillary services tailored to the needs of fibromyalgia patients in China. Market segmentation may be done based on age, gender, severity of symptoms, and geographic area of the customers. Thus, it can be achieved on target market via focused marketing actions. That strive to reach such audiences, the message should reflect its particular needs and expectations. In this regard, the development of strategic partnerships and alliances with healthcare practitioners (HCPs) who have a specialization in treating fibromyalgia could be the key. It entails disseminating flyers, brochures, course materials and responding to patients' inquiries, as well as patient care rehab or training programs. Educating the patients regarding fibromyalgia, its symptoms, treatment options and the role of the company’s products and/or services in managing the condition is advantageous in galvanizing and establishing brand faithfulness and trust. The conducting clinical trials in China not only prove that the product is effective and safe but having approval of regulatory authority and acceptance among medical professionals also facilitates gaining of the approval and acceptance of both patients and physicians. Aligning with hospitals, health clinics, patient support groups, or other target organizations may bring widespread visibility and brand legitimacy among the Chinese fibromyalgia population. While pricing the product or service at a competitive level with respect to its value proposition and being mindful of the affordability of the target market is essential for infiltration and movement of the market. Picking up the most suitable distribution channels is the key gate to the market growth and to the hits targeting both medical institutions and retail channels all over China. Here, they can either keep dealing with local distributors or even go ahead to establish sales channels of their own. Compliance with Chinese regulatory norms along with obtaining clearance of the health authorities in China demonstrates the reliability of the product to the healthcare professionals and patients alike regarding the safety and efficacy. The business environment is subject to the evolution, which means that the relevant competitive dynamics are to be monitored thoroughly to review consumers, regulations and industry trends as soon as possible in order to result in an effective adaptation of the strategy. Implementing comprehensive support PROGRAMS for patients that aim at medication compliance, lifestyle management and access to support networks can induce patient confidence and loyalty. The intelligence from market research data, patient input, and real-world evidence is timely and reliable resource which assists in creating, adapting and constant update of strategies in line with market demands.

Investing in brand building activities and maintaining a positive reputation through ethical business practices and high-quality products or services is essential for long-term success in the Chinese fibromyalgia market. Regularly assessing competitor strategies, strengths, and weaknesses enables the company to identify gaps in the market and capitalize on opportunities for differentiation and growth.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

Market Summary

The Global Chinese Fibromyalgia Market is projected to grow significantly from 13.9 USD Billion in 2024 to 32.2 USD Billion by 2035.

Key Market Trends & Highlights

Chinese Fibromyalgia Market Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate (CAGR) of 7.91% from 2025 to 2035.
  • By 2035, the market valuation is anticipated to reach 32.2 USD Billion, indicating robust growth potential.
  • In 2024, the market is valued at 13.9 USD Billion, laying a strong foundation for future expansion.
  • Growing adoption of innovative treatment methods due to increasing awareness of fibromyalgia is a major market driver.

Market Size & Forecast

2024 Market Size 13.9 (USD Billion)
2035 Market Size 32.2 (USD Billion)
CAGR (2025-2035) 7.91%
Largest Regional Market Share in 2024 latin_america)

Major Players

Pfizer, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, GlaxoSmithKline, AstraZeneca, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS

Market Trends

Chinese Fibromyalgia Market Market Drivers

Market Growth Projections

The Global Chinese Fibromyalgia Market Industry is poised for substantial growth, with projections indicating a market size of 13.9 USD Billion in 2024 and a potential increase to 32.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 7.91% from 2025 to 2035, highlighting the increasing investment in research, treatment options, and patient education. The market's expansion is likely to be driven by a combination of rising prevalence, advancements in treatment modalities, and growing awareness among patients and healthcare providers.

Increased Awareness and Education

Enhanced awareness and education regarding fibromyalgia are crucial drivers for the Global Chinese Fibromyalgia Market Industry. Educational programs aimed at healthcare professionals and the general public are essential in improving understanding of the condition, its symptoms, and treatment options. As more individuals become informed about fibromyalgia, they are more likely to seek medical advice and treatment. This increased awareness is expected to translate into higher market demand, as evidenced by the projected growth from 13.9 USD Billion in 2024 to 32.2 USD Billion by 2035.

Rising Prevalence of Fibromyalgia

The increasing prevalence of fibromyalgia globally is a primary driver for the Global Chinese Fibromyalgia Market Industry. As awareness of this chronic pain condition grows, more individuals are seeking diagnosis and treatment options. Recent estimates suggest that fibromyalgia affects approximately 2 to 4% of the population worldwide, with a notable incidence in China. This rising awareness and diagnosis are likely to contribute to the market's growth, projected to reach 13.9 USD Billion in 2024 and potentially 32.2 USD Billion by 2035, indicating a robust demand for therapeutic solutions.

Government Initiatives and Support

Government initiatives aimed at improving healthcare access and awareness for chronic pain conditions are pivotal for the Global Chinese Fibromyalgia Market Industry. In China, various health policies are being implemented to enhance the diagnosis and treatment of fibromyalgia. These initiatives include funding for research, public health campaigns, and the integration of fibromyalgia management into primary healthcare systems. Such support is likely to foster an environment conducive to market growth, as it encourages healthcare providers to adopt new treatment protocols and improves patient access to necessary therapies.

Advancements in Treatment Modalities

Innovations in treatment modalities for fibromyalgia are significantly influencing the Global Chinese Fibromyalgia Market Industry. The development of new pharmacological treatments, including novel analgesics and antidepressants, has expanded the therapeutic landscape. Additionally, non-pharmacological approaches such as cognitive behavioral therapy and physical rehabilitation are gaining traction. These advancements not only enhance patient outcomes but also encourage more individuals to seek treatment. As a result, the market is expected to experience a compound annual growth rate of 7.91% from 2025 to 2035, reflecting the growing investment in research and development.

Growing Demand for Alternative Therapies

The increasing demand for alternative therapies among patients with fibromyalgia is shaping the Global Chinese Fibromyalgia Market Industry. Many individuals are exploring complementary and alternative medicine options, such as acupuncture, herbal remedies, and mindfulness practices, to manage their symptoms. This trend reflects a broader shift towards holistic health approaches, which are perceived as beneficial in alleviating chronic pain. The market's response to this demand is evident in the rising availability of alternative treatment options, which may contribute to the overall growth trajectory of the industry.

Market Segment Insights

Chinese Fibromyalgia Market Segmentat Insights

The chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the chinese fibromyalgia market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the chinese fibromyalgia market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the chinese fibromyalgia market is segmented into hospitals, clinics, diagnostic centers, and others.

Research Methodology

Get more detailed insights about Chinese Fibromyalgia Market Research Report- Forecast to 2035

Regional Insights

Key Companies in the Chinese Fibromyalgia Market market include

Industry Developments

Future Outlook

Chinese Fibromyalgia Market Future Outlook

The Chinese Fibromyalgia Market is projected to grow at a 7.91% CAGR from 2024 to 2035, driven by increasing awareness, innovative therapies, and enhanced healthcare access.

New opportunities lie in:

  • Develop digital health platforms for remote patient monitoring and support.
  • Invest in research for novel pain management therapies targeting fibromyalgia symptoms.
  • Expand partnerships with healthcare providers to improve patient education and treatment adherence.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and increased patient engagement.

Market Segmentation

Report Scope

Report Attribute/Metric Details  
  Market Size   USD 21.53 Billion  
  CAGR   14.32%  
  Base Year   2023  
  Forecast Period Market Size 2023 13.45 (USD Billion)
  Historical Data Market Size 2024 13.93 (USD Billion)
  Forecast Units Market Size 2032 21.53 (USD Billion)
  Report Coverage Compound Annual Growth Rate (CAGR) 14.32 % (2024 - 2032)
  Segments Covered Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Geographies Covered Base Year 2023
  Key Vendors Market Forecast Period 2024 - 2032
  Key Market Opportunities Historical Data 2019 - 2023
  Key Market Drivers Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth.   

FAQs

  1. Report Prologue
  2. Market Introduction
    1. Research Objective
    2. Assumptions & Limitations 12
      1. Assumptions 12
    3. Limitations 12
  3. Research Methodology
    1. Research Process 14
    2. Primary Research 15
    3. Secondary Research 15
    4. Market Size Estimation
  4. Market Dynamics
    1. Introduction 18
    2. Drivers 19
      1. Rising Incidences of Traumatic Stress and Road Accidents 19
      2. Increasing
      3. Growing Awareness among the population
      4. Increasing geriatric population 22
    3. Cases of Rheumatic Diseases 20
    4. Restraints 23
    5. Difficulty in Diagnosis 23
    6. Opportunities 24
      1. Unmet Medical Need
    7. in Fibromyalgia Treatment 24
    8. Mega Trends 24
      1. Chinese Treatment
      2. Pipeline Drugs 24
    9. Options 24
    10. Macroeconomic Indicators 25
  5. Market
    1. Factor Analysis
    2. Value Chain Analysis 27
      1. R&D 27
      2. Distribution & Sales 27
      3. Post-Sales Monitoring
    3. Manufacturing 27
    4. Porter’s Five Forces Model 28
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers 29
      3. Threat of New Entrant 29
      4. Threat of Substitute 29
      5. Intensity of Rivalry 29
    5. Demand
    6. & Supply: Gap Analysis 30
    7. Pricing Analysis 30
    8. Investment Opportunity
    9. Analysis 30
  6. Chinese Fibromyalgia Market, By Diagnosis
    1. Introduction
    2. Laboratory Evaluation 33
    3. Presence of Central Sensitization
  7. Global and China Fibromyalgia Market, By Treatment
    1. Introduction
    2. Introduction 37
    3. Targeted Treatment 38
    4. Symptomatic
    5. treatment 39
  8. Chinese Fibromyalgia Market, By End Users
    1. Introduction
    2. Hospitals 42
    3. Clinics 42
    4. Diagnostic Centers 43
  9. Chinese Fibromyalgia Market, By Regions
    1. Introduction 45
    2. North
    3. China 46
    4. Northwest China 47
    5. East China 49
    6. South Central
    7. China 50
    8. South West China 52
  10. Competitive landscape
    1. Introduction 55
  11. Company Profiles
    1. Pfizer 57
      1. Financials
      2. Products 57
      3. Strategy 57
      4. Key Developments
    2. GlaxoSmithKline 58
      1. Financials 58
      2. Products 58
      3. Strategy 58
      4. Key Developments 58
    3. AstraZeneca 59
      1. Financials 59
      2. Products 59
      3. Strategy 59
    4. Key Developments 59
    5. Roche 60
      1. Financials 60
      2. Products
      3. Strategy 60
      4. Key Developments 60
    6. Astellas Pharma
      1. Financials 61
      2. Products 61
      3. Strategy 61
      4. Key Developments 61
    7. Eli Lilly and Company 62
      1. Financials
      2. Products 62
      3. Strategy 62
      4. Key Developments
    8. Johnson & Johnson 63
      1. Financials 63
      2. Products
      3. Strategy 63
      4. Key Developments 63
    9. SANOFI 64
      1. Financials 64
      2. Products 64
      3. Strategy 64
    10. Key Developments 64
    11. Bayer 65
      1. Financials 65
      2. Products
      3. Strategy 65
      4. Key Developments 65
    12. AbbVie 66
      1. Financials 66
      2. Products 66
      3. Strategy 66
    13. Key Developments 66
    14. ALLERGAN 67
      1. Financials 67
      2. Strategy 67
      3. Key Developments 67
    15. Products 67
    16. Conclusion
    17. Key Findings 69
      1. From CEO’s View Point 69
    18. Key companies to watch 69
  12. Appendix
    1. Discussion Blue
    2. Print 71
  13. List of Tables
  14. MARKET SYNOPSIS 10
  15. CHINESE
  16. FIBROMYALGIA MARKET, BY DIAGNOSIS 2023-2030 (USD MILLION) 32
  17. CHINESE
    1. FIBROMYALGIA MARKET FOR LABORATORY EVALUATION 2023-2030 (USD MILLION) 33
    2. TABLE
  18. CHINESE FIBROMYALGIA MARKET FOR PRESENCE OF CENTRAL SENSITIZATION 2023-2030 (USD
    1. MILLION) 34
  19. GLOBAL FIBROMYALGIA MARKET, BY TREATMENT 2023-2030 (USD
    1. MILLION) 36
  20. CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2023-2030 (USD
    1. MILLION) 37
  21. CHINESE FIBROMYALGIA MARKET FOR TARGETED TREATMENT 2023-2030
    1. (USD MILLION) 38
  22. CHINESE FIBROMYALGIA MARKET FOR SYMPTOMATIC TREATMENT
  23. CHINESE FIBROMYALGIA MARKET, BY END USER
  24. CHINESE FIBROMYALGIA MARKET FOR HOSPITALS
  25. CHINESE FIBROMYALGIA MARKET FOR CLINICS
  26. CHINESE FIBROMYALGIA MARKET FOR DIAGNOSTIC
    1. CENTERS 2023-2030 (USD MILLION) 43
  27. CHINESE FIBROMYALGIA MARKET, BY
    1. REGIONS 2023-2030 (USD MILLION) 45
  28. NORTH CHINA CHINESE FIBROMYALGIA
  29. MARKET, BY DIAGNOSIS 2023-2030 (USD MILLION) 46
  30. NORTH CHINA CHINESE
  31. FIBROMYALGIA MARKET, BY TREATMENT 2023-2030 (USD MILLION) 46
  32. NORTH
  33. CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2023-2030 (USD MILLION) 47
    1. TABLE
  34. NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2023-2030 (USD MILLION)
  35. NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2023-2030
    1. (USD MILLION) 48
  36. NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY END
    1. USER 2023-2030 (USD MILLION) 48
  37. EAST CHINA CHINESE FIBROMYALGIA MARKET,
    1. BY DIAGNOSIS 2023-2030 (USD MILLION) 49
  38. EAST CHINA CHINESE FIBROMYALGIA
  39. MARKET, BY TREATMENT 2023-2030 (USD MILLION) 49
  40. EAST CHINA CHINESE
  41. FIBROMYALGIA MARKET, BY END USER 2023-2030 (USD MILLION) 50
  42. SOUTH
  43. CENTRAL CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2023-2030 (USD MILLION)
  44. SOUTH CENTRAL CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2023-2030
    1. (USD MILLION) 51
  45. SOUTH CENTRAL CHINA CHINESE FIBROMYALGIA MARKET,
    1. BY END USER 2023-2030 (USD MILLION) 51
  46. SOUTH WEST CHINA CHINESE FIBROMYALGIA
  47. MARKET, BY DIAGNOSIS 2023-2030 (USD MILLION) 52
  48. SOUTH WEST CHINA CHINESE
  49. FIBROMYALGIA MARKET, BY TREATMENT 2023-2030 (USD MILLION) 52
  50. SOUTH
  51. WEST CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2023-2030 (USD MILLION) 53
  52. List of Figures
  53. MARKET STRUCTURE 12
  54. RESEARCH
    1. PROCESS 14
  55. VALUE CHAIN: CHINESE FIBROMYALGIA MARKET 27
    1. FIGURE
  56. PORTERS FIVE FORCES ANALYSIS: CHINESE FIBROMYALGIA MARKET 28
  57. CHINESE
  58. FIBROMYALGIA MARKET, BY DIAGNOSIS 2023 & 2030 (USD MILLION) 33
    1. FIGURE 6
  59. GLOBAL FIBROMYALGIA MARKET, BY TREATMENT 2023 & 2030 (USD MILLION) 36
    1. FIGURE
  60. CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2023 & 2030 (USD MILLION) 38
  61. CHINESE FIBROMYALGIA MARKET, BY END USER 2023 & 2030 (USD MILLION)
  62. CHINA FIBROMYALGIA MARKET SHARE, BY REGION MARKET, 2023 (%) 45
  63. CHINA FIBROMYALGIA MARKET SHARE ANALYSIS, 2023 (%) 55

Chinese Fibromyalgia Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions